11/13
08:05 am
artv
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
High
Report
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
11/13
06:16 am
artv
Rating for ARTV
High
Report
Rating for ARTV
11/13
06:16 am
artv
Rating for ARTV
High
Report
Rating for ARTV
8/31
12:42 am
artv
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Medium
Report
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
8/31
12:42 am
artv
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Medium
Report
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
8/30
12:16 pm
artv
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Medium
Report
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
8/30
11:56 am
artv
Rating for ARTV
Low
Report
Rating for ARTV
8/30
11:56 am
artv
Rating for ARTV
Low
Report
Rating for ARTV